These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27129075)

  • 1. Effects of target binding kinetics on in vivo drug efficacy: koff , kon and rebinding.
    Vauquelin G
    Br J Pharmacol; 2016 Aug; 173(15):2319-34. PubMed ID: 27129075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct in vivo target occupancy by bivalent- and induced-fit-like binding drugs.
    Vauquelin G
    Br J Pharmacol; 2017 Dec; 174(23):4233-4246. PubMed ID: 28838028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the 'micro'-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action.
    Vauquelin G
    Expert Opin Drug Discov; 2015 Oct; 10(10):1085-98. PubMed ID: 26165720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity analysis of binding kinetics for NMDA receptor competitive antagonists: the influence of conformational restriction.
    Benveniste M; Mayer ML
    Br J Pharmacol; 1991 Sep; 104(1):207-21. PubMed ID: 1686203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation.
    de Witte WEA; Vauquelin G; van der Graaf PH; de Lange ECM
    Eur J Pharm Sci; 2017 Nov; 109S():S83-S89. PubMed ID: 28502676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.
    Vauquelin G; Charlton SJ
    Br J Pharmacol; 2010 Oct; 161(3):488-508. PubMed ID: 20880390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models.
    de Witte WEA; Rottschäfer V; Danhof M; van der Graaf PH; Peletier LA; de Lange ECM
    J Pharmacokinet Pharmacodyn; 2018 Aug; 45(4):621-635. PubMed ID: 29777407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
    Maas BM; Cao Y
    MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial.
    Ren T; Zhu X; Jusko NM; Krzyzanski W; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2022 Oct; 49(5):493-510. PubMed ID: 36040645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic mechanism of a partial folding reaction. 2. Nature of the transition state.
    Goldberg JM; Baldwin RL
    Biochemistry; 1998 Feb; 37(8):2556-63. PubMed ID: 9485405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time.
    Vauquelin G
    Expert Opin Drug Discov; 2010 Oct; 5(10):927-41. PubMed ID: 22823988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of the kinetic constants for binding of epinephrine to beta-adrenergic receptors of the S49 cell.
    Stickle D; Barber R
    Biochem Pharmacol; 1991 Aug; 42(5):1069-77. PubMed ID: 1651730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of allosteric modulation: Exploring the binding kinetics of glutamate and other orthosteric ligands of the metabotropic glutamate receptor 2.
    Doornbos MLJ; Vermond SC; Lavreysen H; Tresadern G; IJzerman AP; Heitman LH
    Biochem Pharmacol; 2018 Sep; 155():356-365. PubMed ID: 30028996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic mechanism of a partial folding reaction. 1. Properties Of the reaction and effects of denaturants.
    Goldberg JM; Baldwin RL
    Biochemistry; 1998 Feb; 37(8):2546-55. PubMed ID: 9485404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel, label-free, pre-equilibrium assay to determine the association and dissociation rate constants of therapeutic antibodies on living cells.
    Janezic EM; Doan A; Mai E; Bravo DD; Wang J; Kim HS; Spiess C; Bewley K; ElSohly A; Liang WC; Koerber JT; Richalet P; Vanhove M; Comps-Agrar L
    Br J Pharmacol; 2024 Oct; 181(20):3836-3855. PubMed ID: 37783572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying biological activity in chemical terms: a pharmacology primer to describe drug effect.
    Kenakin T
    ACS Chem Biol; 2009 Apr; 4(4):249-60. PubMed ID: 19193052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of thermodynamic and kinetic data in drug discovery: decisive insight or increasing the puzzlement?
    Klebe G
    ChemMedChem; 2015 Feb; 10(2):229-31. PubMed ID: 25537429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients.
    de Witte WE; Wong YC; Nederpelt I; Heitman LH; Danhof M; van der Graaf PH; Gilissen RA; de Lange EC
    Expert Opin Drug Discov; 2016; 11(1):45-63. PubMed ID: 26484747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.
    Kapur S; Seeman P
    J Psychiatry Neurosci; 2000 Mar; 25(2):161-6. PubMed ID: 10740989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.